A practical reference on metabolic research: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-28 and is reviewed periodically as new material appears.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized form; visual inspection |
| Solubility | Soluble in water and aqueous buffers | Depends on pH, purity, and counterion |
| Typical storage | -20 °C or below, desiccated | Protect from light; avoid repeated freeze-thaw after reconstitution |
| Common analytical method | Reversed-phase HPLC and mass spectrometry | Purity by HPLC; identity and mass by LC-MS or MALDI-TOF |
| Common synonyms | hGH fragment 176–191; AOD-9604 | Names vary in research and product labeling |
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Polyacrylamide gel electrophoresis (PAGE) is used for separating proteins ranging in size from 5 to 2,000 kDa due to the uniform pore size provided by the polyacrylamide gel. Pore size is controlled by modulating the concentrations of acrylamide and bis-acrylamide powder and by the polymerization time used in creating a gel. Care must be used when creating this type of gel, as acrylamide is a potent neurotoxin in its liquid and powdered forms. Traditional DNA sequencing techniques such as Maxam-Gilbert or Sanger methods used polyacrylamide gels to separate DNA fragments differing by a single base-pair in length so the sequence could be read. Most modern DNA separation methods now use agarose gels, except for particularly small DNA fragments. It is currently most often used in the field of immunology and protein analysis, often used to separate different proteins or isoforms of the same protein into separate bands. These can be transferred onto a nitrocellulose or PVDF membrane to be probed with antibodies and corresponding markers, such as in a western blot. Typically resolving gels are made in 4%, 6%, 8%, 10%, 12% or 15% T. Stacking gel (5% T) is poured on top of the resolving gel and a gel comb (which forms the wells and defines the lanes where proteins, sample buffer, and ladders will be placed) is inserted. The percentage chosen depends on the size of the protein that one wishes to identify or probe in the sample. The smaller the known weight, the higher the percentage that should be used.
== Career == In 2007, Wettlaufer was hired onto the staff at Caressant Care, a long-term care home in Woodstock. She was initially regarded by co-workers as caring and professional. However, throughout her tenure, Wettlaufer struggled with substance abuse and alcoholism. She faced accusations of showing up to work drunk, and at one point was found passed out in the facility's basement during the night shift. Wettlaufer was suspended four times for "medication-related errors", then was finally fired in March 2014 over a "serious" incident in which she gave the wrong medication to a patient. After leaving Caressant Care, Wettlaufer had difficulty holding down a job. She was hired by the Meadow Park Care Center in London, but lost this job after checking herself into a drug rehab facility in the Niagara Region. She took various temp jobs at other care homes. Wettlaufer admitted to a neighbour that she was fired from one of these jobs for stealing medication, and was fired from another job for making a medication error while high that nearly resulted in the death of a patient. She also wrote poetry about her desire to kill.
Also in 1978, the Victorian Education Department under the direction of the Deputy Premier and Minister of Education, Lindsay Thompson, established the Victorian College of the Arts Technical School, a government secondary school for dancers and musicians (see Victorian College of the Arts Secondary School) in close association with the VCA and located on the same campus.
Sources: en.wikipedia.org
== Research career and academic posts == After completing graduate school, Fenn's first job was with Monsanto, working in the Phosphate Division and producing polychlorinated biphenyls (PCBs). Fenn and his colleague James Mullen became disenchanted with the direction of work at Monsanto, and they resigned together in 1943. Fenn worked briefly at a small company named Sharples Chemicals that focused on the production of amyl chloride derivatives. In 1945, he joined Mullen at his new startup, Experiment, Inc, focusing on research and development. Fenn's first publication came in 1949 as a result of his work with Mullen. That this publication came ten years after he completed graduate school made Fenn somewhat of a rarity amongst academics. In 1952, Fenn moved to Princeton University as Director of Project SQUID, a program to support research related to jet propulsion that was funded by the Office of Naval Research. During this period, Fenn started his work developing supersonic atomic and molecular beam sources, which are now widely used in chemical physics research. After working with Project SQUID, Fenn returned to Yale University in 1967. He held a joint appointment in the chemistry and engineering departments until 1987, conducting much of his research in Mason Laboratory. In 1987, Fenn had reached Yale's mandatory retirement age. He became a professor emeritus, entitling him to office space at the university, but costing him most of his laboratory space and research assistants.
=== Vaccination and information === Modern societies are facing the challenge of "rational" exemption, i.e. the family's decision to not vaccinate children as a consequence of a "rational" comparison between the perceived risk from infection and that from getting damages from the vaccine. In order to assess whether this behavior is really rational, i.e. if it can equally lead to the eradication of the disease, one may simply assume that the vaccination rate is an increasing function of the number of infectious subjects:
30 October – Dairy company Fonterra's farmer shareholders vote to authorise the sale of several brands including Mainland and Anchor to French company Lactalis. New Zealand First leader and cabinet minister Winston Peters denounces the sale as "short-sighted." Health New Zealand has confirmed two new cases of measles, bringing the total number of active cases to 13. The number of close contacts has risen to 2,142. 31 October: The Waitangi Tribunal rules that the Citizenship Act 1977 breaches the Treaty of Waitangi by limiting eligibility for citizenship by descent for Māori people to one generation and failing to recognise Māori as tangata whenua ("People of the Land"). A power outage affects 23,000 homes and businesses in the Far North District. Auckland Grammar School instructs Years 9 and 10 students to remain at home after a student tested positive for measles.
Sources: en.wikipedia.org
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.
Mass spectrometry, such as LC-MS or MALDI-TOF, confirms the molecular mass and can reveal sequence-related impurities. Reversed-phase HPLC is used for purity, and peptide mapping or amino acid analysis can support sequence identity. No single method establishes every quality attribute.
No. AOD9604 is a short synthetic fragment of the hGH sequence, not the full 191-amino-acid hormone. It lacks the regions that mediate hGH receptor activation and growth-promoting effects. Products labeled as AOD9604 should not be assumed to have the same properties as hGH.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.